Tissue injury is associated with decreased cellular immunity and enhanced metabolism. Immunodepression is thought to be counteracted by interferon-gamma (IFN-γ), which increases human leukocyte antigen-DR (HLA-DR) expression. Hypermetabolism could be enhanced by IFN-γ since cytokines induce an hypermetabolic response to stress. In healthy humans IFN-γ enhanced HLA-DR expression without effects on glucose and fat metabolism. In the present study we evaluated whether IFN-γ lacks potential harmful side effects on metabolic and endocrine pathways while maintaining its beneficial effects on the immune system under conditions in which the inflammatory response system is activated. We studied in thirteen patients scheduled for major surgery, HLA-DR expression on peripheral blood monocytes prior to surgery and postoperatively randomized the patients into an intervention and placebo group. Subsequently, we evaluated the effects of a single dose of IFN-γ vs. saline, on short-term monocyte activation, glucose and lipid metabolism and glucose and lipid regulatory hormones.
Introduction
Tissue injury is associated with decreased expression of human leukocyte antigen-DR (HLA-DR) on monocytes (2; 15; 16; 20; 22; 37) . Low levels of HLA-DR on monocytes are an ominous prognostic factor in the recovery of surgical patients, since reduced HLA-DR expression (or a defective antigen presentation or cellular immunity) is correlated with increased post-operative complications and mortality (18) . Downregulation of HLA-DR expression on monocytes may partly be related to a surgically directed shift of the T-helper 1 (Th1)/Th2 balance toward a dominating Th2 type immune response (7). Compared to pre-operative production, postoperatively stimulated peripheral blood mononuclear cells (PBMC) produce significantly more Th2 cytokine interleukin (IL)-4 than its Th1 counterpart interferon-gamma (IFN-γ) (7; 24).
Administration of IFN-γ enhances the expression of HLA-DR on monocytes in vitro and in vivo (17). Several small to intermediate-sized clinical trials have addressed the effect of IFN-γ
on HLA-DR expression and clinical recovery after sepsis (21) and severe injury (8; 11; 28; 38) .
These studies suggest that administration of IFN-γ to surgical patients could have positive effects on post-operative recovery and prevention of complications, although the data are ambiguous at present (10; 25) .
In addition to the reduction in cellular immunity, another -potentially harmful-side effect of surgical interventions is the metabolic response to stress (26; 39). This response, which is characterised by catabolic reactions such as increases in glucose production, lipolysis and protein turnover, is mediated by the interaction between hormones, inflammatory mediators and the central nervous system (13; 30) . Administration of inflammatory mediators like tumor necrosis factor (TNF)-α, IFN-α, IL-2 or IL-6 to humans, mimics the catabolic changes observed after tissue injury, with specific effects for each individual cytokine (4; 33; 36) . In a previous study, by 10 .220.32.246 on September 22, 2017 http://jap.physiology.org/
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Study design
One day prior to the surgical procedure, blood was sampled for measurement of HLA-DR expression on monocytes and routine biochemical and haematological measurements (including bilirubin). From 06.00 P.M. at the pre-operative day till 05.00 P.M. at the second post-operative day, patients were only permitted to drink water in accordance with the protocol for this surgical procedure.
During surgical intervention, patients were anesthesized using isoflurane and sufentanyl supplemented with drugs provided to the discretion of the anaesthesiologist. Moreover, a high thoracic epidural catheter was inserted through which marcaine was administered. At the first postoperative day, patients were transferred from the recovery room to the general surgical ward. From 0.00 A.M. at the first post-operative day until 5.00 P.M at the second post-operative day, intravenous infusion fluids were limited to saline. Oral food supply or usage of the feeding jejunostomy was only allowed from 06.00 P.M. the second post-operative day onwards according to the treatment protocol.
Analgesics were prescribed according the standard hospital protocol (paracetamol, morphine and epidural marcaine). Additionally, all patients received Fraxiparin® (Sanofi, Maassluis, The Netherlands) and Sandostatin® (Novartis Pharma LtD. Bazel, Swiss).
On the second post-operative day patients were randomized to the IFN-γ or control group by balanced assignment. At 6.45 h A.M., a catheter was placed retrogradely into an antecubital vein for sampling of venous blood. The blood was arterialized by placement of the forearm in a thermoregulated (65 0 C) Plexiglas box during 20 minutes before blood was sampled. Another catheter, situated already in the contralateral hand vein or a central venous catheter -if available-was used for infusion of stable isotope tracers. Both catheters were kept patent by infusion of NaCl 0.65% (30 ml/h). Free fatty acid (FFA) concentrations in plasma were determined using the NEFA C kit (code No 994-75409 E) from Wako Chemicals GmbH (Neuss, Germany). Plasma insulin concentration was measured by RIA (Insulin RIA 100, Pharmacia Diagnostic AB, Uppsala, Sweden; intra-assay coefficient of variation (CV) 3-5%, inter-assay CV 6-9%), C-peptide by RIA (RIA-coat c-peptide, Byk-Sangtec Diagnostics GmbH & Co. KG, Dietzenbach, Germany; intra-assay CV 4-6%, interassay CV 6-8%). Glucagon was determined by RIA (Linco Research, St Charles, MO; detection limit 15 ng/L, intra-assay CV 3-5%, inter-assay CV 9-13%). Cortisol was measured using a luminescence enzyme immunoassay, Immulite (Cortisol, Diagnostic Products Corporation, LA, intra-assay CV 5.8%, inter-assay CV 7.0%), adrenocorticotropic hormone (ACTH) by ILMA (Immuno Lumino Metric Assay)(Nichols Institute, Los Angeles, CA; intra-assay CV 4.3%, interassay CV 5.4 %, resp.), growth hormone (GH) by ILMA (Nichols Institute, Los Angeles, CA; detection limit 1 mU/L, intra-assay CV 7.3, inter-assay CV 9.6%, resp). Catecholamines were measured by in-house HPLC method. Norepinephrine (inter-assay CV 13%, intra-assay CV 6 %) 9 and epinephrine (inter-assay CV 14%, intra-assay CV 7%) were selectively isolated by liquid-liquid extraction and derivatized to fluorescent components with 1,2-diphenylethylenediamine. The fluorescent derivatives were separated by reversed phase liquid chromatography and detected by fluorescence detection (31; 35) IFN-γ was measured using an in-house sandwich ELISA with a detection limit of 31 pg/ml with monoclonal antibody (mAb) MD2 as capture and biotinylated MD1 as detecting mAb, with a detection limit of 31 pg/ml. Monocyte HLA-DR expression was measured using flow cytometry as described previously (6). Cells were incubated with anti-HLA-DR monoclonal antibodies (mAbs) directly labelled with fluorescein isothiocyanate (FITC, Becton Dickinson (BD), San Jose, CA).
Irrelevant mouse mAbs directly labelled with FITC (BD) were used as control for background staining. Data acquisition was performed on a FACScan flow cytometer (BD). Monocytes were gated by forward and side scatter parameters. ), PCT p (t) is the percent enrichment in plasma glucose or glycerol taken as the average of two consecutive samples, p is the pool fraction, V is the distribution volume of glucose (165 ml/kg) or glycerol (235 ml/kg), G(t) is the plasma glucose or glycerol concentration taken as the average of two consecutive samples, dPCT p (t)/dt is the rate of change of percent enrichment in plasma (min -1 ).
To test changes in the laboratory parameters over time within and between groups, data were analysed using analysis of repeated measures by the PROC MIXED procedure of the SAS statistical software release 8.02. Proc Mixed was used to apply analysis of repeated measures modelling fixed and random effects taking into account the covariance of the analysed variables.Except for temperature and glucagon concentrations, this statistical test was performed after logarithmic transformation of the parameters to obtain normal distribution. A p-value of < 0.05 was considered
to represent statistical significance. Only the data from subjects who completed the entire study were used for analysis.
Results
Patient characteristics (table 1)
Initially, 24 patients were included in the study. Post-operatively, 10 patients were excluded from the study, because the tumor was irresectable with concomitant deviation of the pppd procedure. One other patient was excluded on the second post-operative day before IFN-γ/saline was administered, because of cardiac and respiratory instability. Thirteen other patients continued the study on the second post-operative day and were randomly assigned to the placebo or intervention group. Seven patients received 100 µg/m
Clinical effects of IFN-γ
In both study arms the incidence of clinical symptoms as chills, nausea and headache was comparable. There were no differences between the two study arms in baseline body temperature, Monocyte activation ( fig. 1 ).
HLA-DR:
Pre-operatively, HLA-DR expression on peripheral blood monocytes in the 13 patients who completed the study, was 94% (91-96%). On the second post-operative day, just prior to injection of IFN-γ, monocyte HLA-DR expression decreased to 54% (42-60%) and 39% (37-47%) for the intervention and control study, respectively. This decrease did not differ between the two groups. After the intervention, the monocyte HLA-DR expression did not change over time in the control group (p=0.13), whereas in the IFN-γ group the monocyte HLA-DR expression increased to 92% (91-96%) at t=24 hours (p<0.0001), which was different from the control group (p<0.001).
Hormones (table 2)
There were no differences between the two groups in baseline levels of ACTH, cortisol, insulin, Cpeptide, glucagon, growth hormone, epinephrine and norepinephrine. After IFN-γ/saline administration, there were no significant changes in hormone levels within the groups and no differences were measured over time between the groups. 
Substrates of energy metabolism and glucose and glycerol kinetics (fig. 2 and 3)
Glucose: Baseline values of glucose Ra and Rd of glucose did not differ between the 2 study groups. There was no effect of IFN-γ on plasma glucose levels and there were no differences measured in time between both study groups. There was a significant decline, which was most marked in the first study hour, in both Ra and Rd of glucose in the IFN-γ and control groups (p=0.0001, change within group for both Ra and Rd after IFN-γ), whereas there were no differences over time between the IFN-γ and control group.
Fat:
Baseline values of plasma FFA, plasma glycerol, Ra and Rd glycerol did not differ between the two study groups. There was no effect measured in time on plasma FFA and glycerol levels within the groups, nor between the groups. For Ra and Rd glycerol levels there was no effect of IFN-γ in time within the group, although there was a significant difference in time between the IFN-γ and control group (p<0.05 for both Ra and Rd of glycerol).
Discussion
In the present study, we evaluated in post-operative patients, the short term effects of IFN-γ on immunological, endocrine and metabolic parameters. The surgical intervention induced a reduction of monocyte HLA-DR expression, that was restored by IFN-γ. IFN-γ did not induce effects on plasma glucose levels, glucose turnover or glucoregulatory hormone concentrations. Moreover, IFN-γ had no effect on parameters of lipolysis. Therefore, similar to results obtained in healthy volunteers The present study is the first study in which pre-operative and post-operative levels and the effects of IFN-γ administration on HLA-DR expression on monocytes were measured in one combined study. Enhanced levels of HLA-DR expression on monocytes after IFN-γ injection compared to controls have been described previously in post-operative patients with colon cancer, severely injured patients and in septic patients (21; 23; 40) . In contrast to the present study, in none of these studies there were measurements performed prior to (elective) trauma or the disease. In the patients with colon cancer, IFN-γ treatment (200 µg/d) was started 3 to 4 weeks after curative elective surgery and HLA-DR expression was measured after 1 month of treatment (40) . In these patients HLA-DR expression increased from 88% at baseline to 97% after 1 month of treatment, whereas post-operative HLA-DR expression stayed low in the control group during the total followup period of 12 weeks. In trauma patients, receiving IFN-γ (100 µg/day), HLA-DR levels on monocytes prior to treatment with IFN-γ were 57% and increased to 76% after two days of treatment with IFN-γ (23). In septic patients, HLA-DR expression on monocytes prior to treatment was 27% and IFN-γ (100 µg/d) increased HLA-DR expression to 62% within 24 h (21) . Our patients presented with HLA-DR expression levels after surgery that were intermediately reduced (50% 2nd day post-operative), but reached higher levels of expression 24 hours post IFN-γ (93%). In all these studies including our own, IFN-γ clearly increased HLA-DR expression, reflecting a significant recovery of monocyte function. The effect of exogenous IFN-γ on monocytes in post-operative patients was obtained despite significantly lower peak levels in plasma IFN-γ compared to our healthy subjects (6). Since the dose of IFN-γ was equal in both studies, it must be concluded that the clearance of IFN-γ is increased after surgery, a finding that has also been described for other mediators like insulin (5).
Cytokines are thought to play an important role in the metabolic response to injury (39) .
Administration of cytokines like TNF-α, IL-6 and IFN-α in humans induces an hypermetabolic state, which is reflected by cytokine-specific elevations in resting energy expenditure and increases in glucose and glycerol turnover (4; 33; 36). IFN-γ, commonly marked as an important proinflammatory cytokine, was regarded to have a comparable effect on hormones and metabolism (3).
In healthy humans, however, IFN-γ only induced a limited increase in REE and did not affect glucose metabolism (6). Again, in the present study in surgical patients, IFN-γ induced no significant effects on endogenous glucose production or glucoregulatory hormone levels as compared to saline administration. The initial decline in both Ra and Rd of glucose in the intervention and control studies, seems not to be mediated by glucoregulatory hormones, since no changes from baseline hormone levels were observed. Therefore, the phenomenon which might be a postoperative effect of the surgical procedure, is possibly mediated by paracrine factors or the neuroendocrine system. In addition, in the present study, IFN-γ also lacked a clear effect on lipolysis. The difference in Ra and
Rd of glycerol in time between the IFN-γ and control group is probably due to relatively high baseline levels in the control subjects and a subsequent regression to the mean during the study within this group. This consideration is based on recent data from our research group. In patients that Previous human studies reported the effects of IFN-γ on HPA-axis activation. Increased cortisol release was unanimously found in these studies, whereas data on modulation of ACTH release are contradictory (6; 14; 19; 32). The studies in which no ACTH increase was measured preceding a cortisol peak suggest the possibility of an ACTH-independent effect of IFN-γ on the adrenal glands (19; 32) . In the present study no effects of IFN-γ on ACTH or cortisol levels could be detected. High baseline cortisol levels in post-operative patients may explain this lack of IFN-γ-effect on plasma cortisol levels. The absence of an effect on ACTH in the present study may be due to the absence of an effect of IFN-γ on the mediator which could account for ACTH release in the previous studies: plasma IL-6, a known stimulator of ACTH release (33) .
It cannot be deduced from our study to what extent IFN-γ administration will result in improvement in clinical outcome. In 3 randomised trials IFN-γ administration to severely injured (trauma/burn) or sepsis patients did not result in definitive improvement in clinical relevant endpoints. Nevertheless, there is reason to believe that high risk patients might benefit from adjuvant IFN-γ therapy (10; 11; 28; 38) .
We conclude that IFN-γ exerts a favourable effect on cell-mediated immunity in patients after major surgery. Moreover, in surgical patients IFN-γ does not have measurable clinical, endocrine or metabolic side effects. 
Figure legends
Fig. 3
Effects of interferon-gamma (IFN-γ) on fat metabolism. Plasma free fatty acids (FFA) and glycerol concentration and the rate of appearance (Ra) and disappearance (Rd) of glycerol after 100 µg/m 
